Bilateral Intravitreal Dexamethasone Implant for Retinitis Pigmentosa-Related Macular Edema

Saatçi, Ali Osman; Selver, Özlem Barut; Seymenoğlu, Göktuğ; Yaman, Aylın

doi:10.1159/000350544

Cited by 27 publications

(19 citation statements)

References 26 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…10,11,12,13 Srour et al 10 administered intravitreal dexamethasone implant in 3 patients with mean central macular thickness (CMT) of 443±185 µm (range 213-619 µm) and mean visual acuity of 20/160 (20/50-20/200) at baseline. One month after dexamethasone implantation, mean CMT improved to 234±68 µm and mean BCVA improved to 20/100.…”

Section: Discussionmentioning

confidence: 99%

“…One month after dexamethasone implantation, mean CMT improved to 234±68 µm and mean BCVA improved to 20/100. Saatci et al 11 reported a case with bilateral ME secondary to RP. Visual acuity of the patient was 2/10 in both eyes and he had been under topical dorzolamide treatment 3 times a day for nearly a year without any change in VA. One week after the injection his visual acuity improved to 4/10 and ME resolved.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intravitreal Dexamethasone Implant (Ozurdex) for Refractory Macular Edema Secondary to Retinitis Pigmentosa

Örnek

Erbahçeci

2016

tjo

View full text Add to dashboard Cite

Macular edema (ME) in retinitis pigmentosa (RP) often impairs central vision dramatically. A 41-year-old woman diagnosed with RP was referred to our outpatient clinic due to severe visual deterioration in both eyes. The patient was treated with topical carbonic anhydrase inhibitors, topical corticosteroids and intravitreal triamcinolone acetonide injections, but her ME recurred. Intravitreal 0.7 mg dexamethasone implant (Ozurdex, Allergan) was administered into both eyes without complications. On the fourth day after both injections, visual acuity improved and ME almost totally resolved. No recurrence was observed at follow-up six months later.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Intravitreal Dexamethasone Implant (Ozurdex) for Refractory Macular Edema Secondary to Retinitis Pigmentosa

Örnek

Erbahçeci

2016

tjo

View full text Add to dashboard Cite

show abstract

“…Il existe 3 cas rapportés dans la littérature d'OM compliquant des rétinopathies pigmentaires traités par injection d'implant de dexaméthasone [35][36][37], et une petite série rétrospective de 4 yeux [38]. Tous décrivent une efficacité sur la réduction d'épaisseur maculaire, mais parfois sans succès fonctionnel, et avec une tendance à la récidive dès 2 à 3 mois après l'injection [35,38].…”

Section: Discussionunclassified

“…Tous décrivent une efficacité sur la réduction d'épaisseur maculaire, mais parfois sans succès fonctionnel, et avec une tendance à la récidive dès 2 à 3 mois après l'injection [35,38].…”

Section: Discussionunclassified

Efficacité des implants intravitréens de dexaméthasone dans l’œdème maculaire hors occlusions veineuses : résultats sur une cohorte de 80 patients

Degoumois

Laurens

Rodallec

et al. 2015

Journal Français d'Ophtalmologie

View full text Add to dashboard Cite

“…The previous reports on intravitreal steroid administration in eyes with RP-related CME [30][31][32][33][34][35][36][37][38][39] are summarised in Table 1. The treatment effect of dexamethasone implant can be seen in a case with bilateral RP-related CME (Figures 1 and 2).…”

Section: -30mentioning

confidence: 99%

Intravitreal Pharmacotherapy in the Treatment of Retinitis Pigmentosa-related Cystoid Macular Oedema

Dönmez¹,

Saatçi²

2017

European Ophthalmic Review

Self Cite

View full text Add to dashboard Cite

P eripheral visual field constriction and night blindness are the main features of retinitis pigmentosa (RP). However, central vision is often impaired dramatically even in the early stages of the disease when macular complications such as cystoid macular oedema (CME) occur. The pathogenesis of RP-related CME is still not well explained. Therefore, several treatment alternatives such as topical, oral and systemic pharmacotherapy; laser photocoagulation and even vitreoretinal surgery are employed by the clinicians. In this review, we summarise the clinical data on intravitreal pharmacotherapeutic agents and focus mainly on the steroids and anti-vascular endothelial growth factor agents. KeywordsAflibercept, intravitreal injection, macula, macular oedema, Ozurdex ® , ranibizumab, retinitis pigmentosa, steroid, vascular endothelial growth factor Disclosure: Oya Donmez and Ali Osman Saatci have nothing to disclose in relation to this article. No funding was received for the publication of this article. This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole and have given final approval for the version to be published.Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit. 1,2 Night blindness together with the peripheral visual field loss is the most prominent clinical feature.1,2 Central vision is relatively spared up to the later stages of the disease process.3 However, when macular complications such as macular oedema arise, central vision is often dramatically impaired even in the early stages of the disease. The prevalence of cystoid macular oedema (CME) is reported to be 10-20% in the eyes of patients with RP. 4,5The pathogenesis of RP-related CME is still unclear. Blood-retinal barrier (BRB) impairment, retinal pigment epithelium (RPE) pump disturbance, inflammation, autoimmunity and vitreoretinal interface changes may be among the potential causes of CME. [6][7][8][9][10][11][12][13][14][15][16][17][18][19] Fishman et al. 6 examined 15 RP patients with vitreous fluorophotometry. All patients showed abnormally high concentrations of fluorescein within the vitreous which was a sign of BRB abnormality. Larsen et al. 7 demonstrated that BRB leakage was markedly increased in six RP patients with the help of ocular spectrofluorophotometry. Vinores et al. 9 investigated the immunohistochemical staining for albumin on paraffin sections of 22 normal and 29 RP eyes.Electron microscopic immunocytochemical staining for albumin was performed on additional six normal and nine RP-affected eyes. Two-thirds of the eyes with RP demonstrated extr...

show abstract

Bilateral Intravitreal Dexamethasone Implant for Retinitis Pigmentosa-Related Macular Edema

Cited by 27 publications

References 26 publications

Intravitreal Dexamethasone Implant (Ozurdex) for Refractory Macular Edema Secondary to Retinitis Pigmentosa

Intravitreal Dexamethasone Implant (Ozurdex) for Refractory Macular Edema Secondary to Retinitis Pigmentosa

Efficacité des implants intravitréens de dexaméthasone dans l’œdème maculaire hors occlusions veineuses : résultats sur une cohorte de 80 patients

Intravitreal Pharmacotherapy in the Treatment of Retinitis Pigmentosa-related Cystoid Macular Oedema

Contact Info

Product

Resources

About